Sh28bn Konza manufacturing park aims to cut drug imports
The part is expected to anchor kenya's ambitions of becoming a regional pharmaceutical manufacturing hub...
✨ Key Highlights
Kenya is considering a Sh27.8 billion biotechnology and pharmaceutical manufacturing park at Konza Technopolis to significantly reduce reliance on imported medicines and active pharmaceutical ingredients (APIs).
- The proposed project, submitted by APIFA Biotech, aims to establish a regional pharmaceutical manufacturing hub.
- A feasibility study is currently underway for the park, which will be developed on 2,000 acres under a Public-Private Partnership (PPP) arrangement.
- The initiative is inspired by India's bulk drug park model, featuring common user facilities to lower production costs for manufacturers and bolster Kenya's pharmaceutical independence, a vulnerability highlighted during the Covid-19 pandemic.
Continue Reading
Read the complete article from Nation Business
Part of the Day's Coverage
Treasury misses tax revenue target by nearly Sh7bn - July 2026
The National Treasury of Kenya narrowly missed its revised tax revenue target for the 2025/26 financial year, falling short by nearly Sh7 billion, indicating ongoing challenges in achieving revenue collection goals. National Treasury Cabinet Secretary John Mbadi has ruled out increasing government borrowing to finance the Sh4.82 trillion budget for the fiscal year 2026/27, despite a reduced revenue projection from the Finance Bill 2026. Separately, Kenya is considering a Sh27.8 billion biotechnology and pharmaceutical manufacturing park at Konza Technopolis to significantly reduce reliance on imported medicines and active pharmaceutical ingredients.
